Stockscreener 앱 받기
5.73
1.96%
0.11
시간 외 거래:
5.64
-0.09
-1.57%
전일 마감가:
$5.62
열려 있는:
$5.41
하루 거래량:
1.46M
Relative Volume:
3.16
시가총액:
$192.71M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-3.6266
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
+60.50%
1개월 성능:
+128.29%
6개월 성능:
+72.59%
1년 성능:
-26.06%
1일 변동 폭
$5.10
$5.74
1주일 범위
$3.54
$6.15
52주 변동 폭
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
5.73 | 192.71M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News
Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance
Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com
Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus
FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus
FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus
Are Fulcrum Therapeutics Inc’shares a good deal? - uspostnews.com
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss - Investing.com
Fulcrum Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c - StreetInsider
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Sells 26,347 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Daily Progress: Fulcrum Therapeutics Inc (FULC) Drop -10.27, Closing at 3.32 - DWinneX
Fulcrum Therapeutics Inc [NASDAQ: FULC] Sees Decrease in Stock Value - knoxdaily.com
Fulcrum Therapeutics to Release First Quarter 2025 Financial Results on May 1, 2025 - Nasdaq
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET - The Manila Times
Earnings Call Alert: Rare Disease Developer Fulcrum Therapeutics Sets Q1 2025 Results Date - Stock Titan
Investing in Fulcrum Therapeutics Inc (FULC) might be a great opportunity, but the stock is a bit overvalued - uspostnews.com
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $8.63 - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Wellington Management Group LLP - Defense World
American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance
Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India
Fulcrum Therapeutics stock hits 52-week low at $2.77 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Sheds Investor Suit Over Blood Treatment Trial Safety - Bloomberg Law News
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire
Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India
Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):